Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
President Donald Trump has consistently demonstrated a preference for maintaining control over escalation rather than allowing events to dictate American strategy.
[T]his blacklist has long since superseded its original military-related purpose and is now Washington’s means of tracking and suppressing China’s top enterprises.